All In Biotech

BLA 761231 · Amneal Pharms LLC

Alymsys

Bevacizumab-Maly · Injection · Vascular Endothelial Growth Factor Inhibitor

Last checked: Nov 20, 2026Latest source record: Apr 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 13, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,998

508 Phase 3, 455 recruiting

FAERS reports

201

176 serious, 38 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 23, 2026.

Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1) Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer. (1.1) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. (1.2) Recurrent glioblastoma in adults. (1.3) Metastatic renal cell carcinoma in combination with interferon alfa. (1.4) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. (1.5) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens (1.6) 1.1 Metastatic Colorectal Cancer Alymsys, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC). Alymsys, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer [see...

Mechanism: Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 13, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • ALYMSYS · BEVACIZUMAB-MALY 400MG/16ML(25MG/ML · INJECTABLE, INJECTION · Prescription
  • ALYMSYS · BEVACIZUMAB-MALY 100MG/4ML(25MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bevacizumab" as an intervention, any sponsor and status, largest first.

All 2,998 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death17
  • asthenia15
  • nausea11
  • neutropenia11
  • decreased appetite10
  • weight increased9
  • fatigue8
  • encephalitis7
  • mucosal inflammation7
  • weight decreased7
  • aspartate aminotransferase increased6
  • blood alkaline phosphatase increased6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202234
202341
202423
202542
202661

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alymsys (Bevacizumab-Maly)

2024 spending

$3.1M

Beneficiaries

126

541 claims

Per beneficiary

$24,947

$173.25 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$485,558
2024$3,143,277

Part B: Alymsys (Bevacizumab-Maly) · HCPCS Q5126

2024 spending

$108M

Beneficiaries

4,482

27,165 claims

Per beneficiary

$24,194

2024 ASP limit $54.26 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$59,629,048
2024$108,437,930

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,932 on PubMed

Sponsor: Amneal Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.